Real-world data show Ocrevus reduced relapse rates and maintained disability stability in relapsing MS over four years.

Should multiple sclerosis (MS) patients stop disease-modifying treatment (DMT) as they get older? The answer depends on several factors, noted John Corboy, MD, of the Rocky Mountain MS Center at the ...

Continued treatment with Briumvi provided sustained clinical benefits to patients with relapsing MS, particularly when ...

Cladribine, a nucleotide (deoxyadenosine) analogue, inhibits deoxyribonucleic acid (DNA) synthesis in proliferating lymphocytes, causing DNA damage and depleting their number by apoptosis and ...

"The observed differential effects of high-efficacy disease-modifying agents across sexes underscore the importance of sex-specific considerations in making treatment decisions to personalize care in ...

A generation ago, most people with multiple sclerosis could expect to rely on walkers and wheelchairs or be limited to their bed within 15 years of diagnosis. Today, UC San Francisco’s discoveries are ...

It helps align clinical practice and reimbursement pathways, ensuring that clinical decision-making and insurance coverage ...

PARIS — The first real guidelines on the use of disease-modifying therapies in multiple sclerosis (MS) have been released by a European joint venture between the European Committee for Research and ...

Key opinion leaders discuss the single FDA-approved option for primary progressive multiple sclerosis and emerging therapies under investigation for this MS subtype, examine the PERSEUS trial, and ...

Multiple sclerosis (MS) is a debilitating autoimmune disease of the brain and spinal cord. The disease can affect everyone differently, but depending on the progression and severity of the disease, ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. March is Multiple Sclerosis Awareness Month, a time to ...